08Sep
07Sep
Myomo’s Wearable Completes First Phase of Brain-Computer Interface Trial
Massachusetts medical robotics provider Myomo has developed MyoPro wearable to offer enhanced functionality to patients with neurological disorders and upper-limb paralysis. It has recently announced that Thomas Jefferson University has conducted the first phase of clinical trials leveraging sensors embedded in the brain to control a MyoPro-boosted brace worn by a stroke patient. Read more >>
06Sep
How Amazon’s cloud business generates billions in profit
...One competing cloud storage provider is privately held Wasabi. Rather than offering a huge range of services like AWS, Wasabi focuses on only data storage, and it charges about one-fifth the price of Amazon S3, said David Friend, Wasabi’s CEO. Read more >>
04Sep
NEXT Venture Pitch finalists
...Billed as the “premiere venture pitch of the Carolinas,” NEXT gives entrepreneurs a chance to pitch ideas to investors, venture capitalists and community leaders. One of the six finalists is: Zylö Therapeutics — Next-gen, topical drug delivery systems. Read more >>
03Sep
Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute
Xylyx Bio, Inc., a biotechnology company developing groundbreaking solutions for drug discovery and tissue modeling and repair, announced today that it has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF). Read more >>
03Sep
eSight glasses help the legally blind to see
eSight Eyewear has created a head-set device that can enhance the vision of people with more than 20 different eye conditions, including macular degeneration, some forms of glaucoma, diabetic retinopathy, and Stargardt disease. Read more >>
02Sep
10 PORTFOLIO COMPANIES TO WATCH IN 2022
10 portfolio companies to watch in 2022 selected by Ziad Moukheiber President Boston Harbor Angels. The list is in alphabetical order / Akston Bioscienceshttps://www.akstonbio.com/ Archer Roosehttps://archerroose.com/ Astrocyte Pharmaceuticalshttps://www.astrocytepharma.com/ Cytoagentshttps://www.cytoagents.com/ Futurefuel.iohttps://futurefuel.io/ Revbiohttps://revbio.com/ S'Morehttps://www.smoredate.com/ Wasabi Technologieshttps://wasabi.com/ Winter Innovationshttps://www.winter-innovations.com/ Xeno Bioscienceshttps://www.xenobiosciences.com/
02Sep
Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery
Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. Read more >>
01Sep